Aquestive Therapeutics (AQST) Amortization of Deferred Charges (2017 - 2026)

Aquestive Therapeutics' Amortization of Deferred Charges history runs 10 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• In Q1 2026, Amortization of Deferred Charges fell 16.87% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at -$221000.0 (down 170.61% YoY), while the FY2025 annual figure was $243000.0, up 2.97% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $2.3 million, up from $62000.0 in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $2.8 million in Q1 2025, with the low at -$7.8 million in Q4 2024.
• The 5-year median for Amortization of Deferred Charges is $61000.0 (2025), against an average of $285294.1.
• Peak annual rise in Amortization of Deferred Charges reached 89000.0% in 2024, while the deepest fall reached 544.01% in 2024.
• Aquestive Therapeutics' Amortization of Deferred Charges stood at $58000.0 in 2022, then surged by 2920.69% to $1.8 million in 2023, then tumbled by 544.01% to -$7.8 million in 2024, then jumped by 100.8% to $62000.0 in 2025, then surged by 3587.1% to $2.3 million in 2026.
• Business Quant data shows AQST's Amortization of Deferred Charges at $2.3 million in Q1 2026, $62000.0 in Q4 2025, and $61000.0 in Q3 2025.